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CLINICAL-EPIDEMIOLOGICAL AND TREATMENT
CHARACTERISTICS OF CHILDREN WITH COVID-19
IN A TERTIARY REFERRAL CENTER IN PERÚ
CARACTERÍSTICAS CLÍNICAS DE NIÑOS CON COVID-19 ADMITIDOS EN UN CENTRO TERCIARIO DE
REFERENCIA EN EL PERÚ
Christian Chiara Chilet1, Medalit Luna Vilchez 1, Julio Maquera-Afaray 1,2, Blanca Salazar Mesones1, Diana Portillo Alvarez1,
Ramiro Priale Miranda1 , Franklin Mendoza1 , Aldo Munayco1 , Mitsi Santiago3 , Jose W. López1,4

ABSTRACT
Introduction: The COVID-19 pandemic has a great impact on children's health. This study describes the characteristics of
hospitalized children at the San Borja National Children's Health Institute in Perú. Methods: This was a retrospective study of
patients with a con rmed diagnosis of COVID-19 from March to July 2020. Demographic, clinical, laboratory, radiological,
and treatment information were collected. Data analysis included descriptive statistics and bivariate analysis to determine
diﬀerences between patients in general wards and the intensive care unit (ICU). Results We included 91 patients, 33 being
females (36.3%). The most aﬀected age group was children > 2 years of age (63 cases) with a median age of 6 years (IQR 3-10),
and 61.5% were from Lima. The previous contact was determined in 30.8% of cases. A positive SARS CoV-2 PCR result was
obtained in 50.6%. The presence of comorbidity was 53.8%. The most frequent symptoms were: fever (39.6%), general
malaise (23.1%), cough (19.8%), and respiratory distress (14.3%). The presence of multisystem in ammatory syndrome in
children (MIS-C) was con rmed in 6 patients. Antibiotics were administered in 76.9%. The most frequent radiological pattern
was bilateral interstitial in ltrates (57.7%). Mortality was higher in patients in the ICU than in the hospitalization ward (27.3%
vs. 4.3%, respectively; p = 0.020). Conclusions: COVID-19 in children presents mild and moderate clinical manifestations.
The presence of comorbidity is an important factor for hospitalization, and mortality is high upon admission to critical care
units.
Keywords: Child; Comorbidity; Coronavirus Infections; Mortality. (Source: MESH-NLM)

RESUMEN
Introducción: La pandemia por COVID-19 representa un gran impacto en salud infantil, en este estudio se describe el
comportamiento de esta enfermedad en pacientes pediátricos hospitalizados en el Instituto Nacional de Salud del Niño San
Borja (INSN-SB) en el Perú. Métodos: Estudio retrospectivo de pacientes con diagnóstico con rmado de COVID-19 durante
marzo a julio de 2020. Se recolectó información demográ ca, clínica, laboratorial, radiológica y de tratamiento, para el
análisis de datos se incluyó estadística descriptiva y un análisis bivariado para determinar las diferencias de pacientes en
salas de hospitalización y la Unidad de cuidados intensivos pediátrico (UCIP). Resultados: Se incluyeron 91 pacientes, 33 de
sexo femenino (36,3%). El grupo etario más afectado fueron los niños > de 2 años de edad (63 casos) con una mediana de
edad de 6 años (RIC 1-8). 61,5% de pacientes procedían de Lima. El resultado de PCR SARS CoV-2 fue positivo en el 50,6%. La
presencia de comorbilidad fue 53,8%. Los síntomas más frecuentes fueron ebre (39,6%), malestar general (23,1%), tos
(19.8%) y di cultad respiratoria (14,3%). La presencia de síndrome in amatorio multisistémico (MIS-C) se con rmó en 6
pacientes. El uso de antibióticos representó 76,9%. El patrón radiológico más frecuente fue intersticial bilateral (57,7%). La
mortalidad fue mayor en pacientes de UCI frente a los de salas de hospitalización (27,3% vs. 4,3%, respectivamente; p =
0.020). Conclusiones: El COVID-19 en niños presenta manifestaciones clínicas leves y moderadas. La presencia de
comorbilidades es un factor importante de hospitalización, y la mortalidad es alta en pacientes admitidos a UCIP.
Palabras clave: Niños; Comorbilidad, Infecciones por Coronavirus; Mortalidad. (Fuente: DeCS- BIREME)
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INTRODUCCIÓN
The coronavirus pandemic is the biggest public health
crisis the world still has to face. It has been estimated
that more than 90% of the cases correspond to the adult
population and only between 1 to 5% occur in the
pediatric population (1), of which more than 90% are
asymptomatic, mild, or moderate forms of presentation,
and only 5.9 % severe cases (2), this percentage is much
lower compared to the 18.5% of severe cases reported
in the adult population (3).

Population and sample
For non-occasionally demonstrated convenience, all
hospitalized patients under 18 years of age with a
laboratory-con rmed diagnosis of COVID-19 who had
the variables of interest were included (N=91). Consult
the medical records of patients treated with COVID-19,
the INSN-SB is a reference pediatric center with 306
beds. For the best care of patients with COVID-19, 24
beds were provided for patients with a con rmed case
of COVID-19, 25 beds for patients with suspected

The association between the presence of comorbidity
and severe disease has been reported in a study of 48

COVID-19, and 12 beds for pediatric patients with PICU
requirements.

pediatric patients admitted to the PICU, of which 40
children (83%) had some comorbidity (4), in another

Eligibility criteria

study that included 651 children, 46% I present at least

Patients with incomplete data were excluded and the

one comorbidity (5). The development of MIS-C has been

clinical evaluation was performed by the pediatrician

described, which can be severe and present signi cant

according to institutional care guidelines. The de nition

cardiac involvement (6). Patients with MIS-C were found

of COVID-19 cases was considered according to the

to have a 5-fold increased risk of being admitted to the

institutional standard of the Peruvian Ministry of Health

(5)

PICU . In Peru, the incidence of COVID-19 in adults will

(MINSA) (8), as well as the de nition of the MIS-C of the

continue to be 13 times higher than in children (7),

World Health Organization (WHO), which includes

however, the behavior of COVID-19 in pediatric patients

children and adolescents from 0 to 19 years old with

with complex comorbidities has not been described.

fever greater than or equal to three days and other
criteria (9).

The aim of this study is to describe the clinical,
epidemiological, and treatment characteristics of
children diagnosed with COVID-19 hospitalized at the
INSN-SB, which is characterized as a highly complex
specialized surgical center.

COVID -19 infec tion was diagnosed by the
immunochromatographic blood test or by the
polymerase chain reaction test of a nasopharyngeal
swab, depending on their availability. In addition, as
part of the hospitalization criteria, con rmatory

METHODS

laboratory tests were performed on asymptomatic

Design and study area

patients prior to the start of chemotherapy or in the

During the period from March 1 to July 31, 2020, a

preoperative period, the tests and images were

retrospective qualitative and quantitative

indicated by the pediatrician and were performed

observational study was carried out.

according to institutional guidelines. (Figure N° 1)
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Pacientes atendidos en el Instituto Nacional
de Salud del Niños San Borja durante los
meses de Marzo a Julio 2020
Pacientes no elegibles por ausencia de
sospecha clínica de COVID-19
n:230
Pacientes con sospecha clínica
de COVID-19
n:576
Caso descartado de COVID-19
n:461
Pacientes con diagnostico laboratorial
de COVID-19
n:115
EXCLUIDOS
Datos Incompletos de Historias Clínicas
n=24
Pacientes incluidos en el análisis
n=91
Con rmados por prueba rápida: 45
Con rmados por prueba molecula:46

Figure 1.
Study variables

(AST) , total bilirubin, alkaline phosphatase, gamma-

The epidemiological variables evaluated were sex, age,
origin by department, weight, height, comorbidity and
direct contact with COVID-19 patients. The clinical
variables included were: date of onset of symptoms and
the presence or absence of symptoms such as malaise,
cough, shortness of breath, diarrhea, abdominal pain,
nausea, vomiting, headache, runny nose, and
pharyngeal pain. The clinical signs considered were
fever, conjunctival injection, rash, dyspnea, snoring,
wheezing, crackles, sub-crackles, seizures, pharyngeal
exudate, pretibial edema or scaling of extremities, and
raspberry tongue.

glutamyl transferase (GGT) prothrombin time (PT), D-

as well as, the hospital stays considering the nal

Procedures

day of July 2020.

dimer.
Treatment received during COVID-19 infection is
described based on drug groups (antibiotics,
antifungals, antivirals, antiparasitics, anticoagulants,
antipyretics, human immunoglobulin, corticosteroids,
and vasoactive drugs). Finally, the severity of the clinical
picture, PICU requirement and admission date were
evaluated, as well as the presence or absence of MIS-C;
condition of the patient and the cut-oﬀ point as the last

Laboratory tests for SARS CoV-2 infection were both
rapid and molecular tests. In addition, the following
were included: hemoglobin, leukocytes, leukocyte
diﬀerential, platelets, albumin, creatinine, ferritin, Creactive protein, procalcitonin, sedimentation rate
(ESR), lac tate dehydrogenase (LDH), alanine
aminotransferase (ALT), aspartate aminotransferase

Statistical analysis
The study data was collected and managed using the
Integrated Hospital Management System (SIS Galen
Plus) (10) and the REDCap electronic data capture tools
(11,12)

hosted at the INSN-SB.
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A descriptive analysis was performed for the variables of
interest; for quantitative variables due to an asymmetric
distribution, medians and interquartile ranges (IQR)
were analyzed, and for qualitative variables, frequency
tables were analyzed.
The bivariate analysis was performed to identify the
diﬀerences between the types of hospitalization
(general wards and PICU), for qualitative variables the
chi-square test and Fisher's test were used, while nonparametric tests were performed for numerical
variables. Statistical analysis was performed with
version 16 of the STATA program (StataCorp. 2019. Stata
Statistical Software: Release 16. College Station, TX:
StataCorp LLC). All diﬀerences were considered with a
value of p < 0.05.

Ethical aspects
This study was approved by the Institutional Research
Ethics Committee of the INSN-SB with project code PI429.

RESULTS
Between March and July 2020, 576 patients were
admitted to the INSN-SB with suspected COVID-19, of
which 19.9% (n=115) had a diagnosis con rmed by
molecular or rapid testing, a total of 91 were analyzed
patients. The majority of patients were male, with the
predominant age group being schoolchildren: 61.5%
(n=56) of the patients came from the city of Lima and
89.1% (n=81) had incomplete vaccination, 100% from
who (n=22) were admitted to the PICU. (Table 1)

Table 1. Demographic characteristics of patients with COVID-19 seen at INSN SB (n=91).
Characteristics
Gender
Female
Male
Age (years)
Source
Lima
Provinces
Incomplete vaccination
Surgical admission
Emergency
Contact

Elective
Family
Patient
Unknown

Diagnostic test
Quick test
Molecular test
X-ray

Normal
Abnormal

Presence of comorbidity
Yes
No
Presence of MIS-C
Yes
No
Patient's nal condition
Live
Deceased
*Medium, RIC
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Regarding comorbidity, they occurred in 53.8% (n=49),
of which 68.8% (n=15) were admitted to the ICU. In
31.2% (n=15) the most frequent comorbidity was
neurological and 24.4% (n=12) cardiological, followed

by 14.2% (n=7) hematological and 14.2% (n=7)
oncological, nally in patients admitted to PICU, the
most frequent comorbidity was cardiological 40% (n =
6) and neurological 20% (n = 3). (Table 2)

Table 2. Comorbidities of patients with COVID-19 seen at INSN-SB (n=91).
Comorbidities
Presence of comorbidity
Yes
No
Type of comorbidty
Neurological
Cardiological
Hematology
Oncology

53.8
46.2
31.2
25.5
14.9
14.9

Gastrointestinal

12.2

Trauma

7.7

Pneumology
Burn
Other

7.7
5.77
3.8

The symptoms reported were general malaise 23.1%
(n=21), cough 19.8% (n=18), respiratory distress 14.3%
(n=13), vomiting 12.1% (n=11); as evidenced signs fever
39.6% (n=36), dyspnea 13.2% (n=12), snoring 9.9%
( n = 9 ) a n d s e i z u r e s 5 . 5 % ( n = 5 ) . ( Ta b l e 3 )
In general, the majority of patients had a normal chest Xray 63.6% (n=14), with diﬀerences evidenced between

children admitted to hospitalization wards and those
admitted to PICU (74% vs 38%, respectively) or
radiological pattern abnormal (26% vs 61.9%,
respectively) (p < 0.01). In addition, the most frequent
radiological pattern was bilateral interstitial in ltrates in
57.7% (n = 15). (Table 3)

Table 3. Clincal and radiological characteristics of patients with COVID-19 seen at INSN-SB (n=91).
Characteristics
Symptoms
General malaise

23,1

Cough

19,8

Respiratory distress

14,3

Vomiting

11,2

Abdominal pain

11,0
Pág. 769
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Rhinorrhea
Nausea
Diarrhea
Pharyngeal pain
Seizures

8.8
6.6
3.3
3.3
2.2

Headache

2.2

Fever
Dyspnea
Snoring
Sibilants
Seizures
Subcrepitant
Adenopathies
Rash
Pretibial edema
Raspberry tongue

39.6
13.2
9.9
5.5
5.5
4.4
4.4
3.3
2.2
1.1

Conjunctival injection

1.1

Signs

Chest radiological pattern
Bilateral interstitial
Unilateral Alveolar
Unilateral interstitial
Bilateral alveolar

Regarding mortality, diﬀerences were observed
between children admitted to hospitalization wards
and those admitted to PICU (4.3% vs 27.3%; p < 0.02).
(Table N° 4)

Table 4.

57.7
30.7
11.5
7.6

In relation to MIS-C, only 6.6% (n = 6) of the patients
presented the criteria established by the WHO, most of
these patients did not require PICU admission (n = 4).

Mortality reported in patients in hospital wards and PICU with COVID-19
attended at INSN-SB (n=22).

Characteristics
Survival
Yes
No

Hospitalization
room
66 (95.6%)
3 (4.3%)
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In the patients who had laboratory tests on admission,
we found that the main laboratory alteration was the
levels of C-Reactive Protein (CRP) 9.4 mg/L (2.1 – 96.7)
and D-Dimer 0.69 ug/ ml(0.27 - 1.65), we did not show
greater alteration with respect to procalcitonin 0.14
(0.05-0.65) or in the values of TGP, AST and creatinine,
with respect to the blood count the median of the
hemoglobin was 11.8 g/dl (9.8 - 12.8), in addition we did
not nd leukocytosis, neutrophilia, left shift or marked
lymphocytopenia (leukocytes at 10800x103/uL(7430 -

1450), lymphocytes 3040x103 /uL (1820-4910),
neutrophils 5045x 103/uL (3095-9240) By IgM serology,
Mycoplasma pneumoniae was the most isolated
microorganism 9.9% (n=9), followed by
Cytomegalovirus 3 .3% (n=3), Epstein Barr 2.2% (n=2)
and In uenza 1.1% (n=1); gram-positive germs were
isolated in 42.9% (n=9), in a smaller proportion were
isolated Gram negative bacteria 38.1% (n=8) and fungi
19% (n=4) (Table 5).

Table 5. Laboratorial and microbiological characteristics of patients with COVID-19 seen
at INSN-SB.

Characteristics
Hematology
Hemoglobin
Leukocytes
Lymphocytes
Monocytes
Neutrophils
Rods
Platelets
Biochemistry

C-reactive protein
ESR
Creatinine
Albumin
AST
GPT
Ferritin
Total Bilirubin

Prothrombin time
Fibrinogen
D-dimer
Pág. 771
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Procalcitonin
CPK
CPK-MB
Lactate
LDH
Microbiology

Mycoplasma
Cytomegalovirus
Epstein Barr
In uenza B
Herpes 1
Parvovirus B19
Type of insulation

Gram positive
Gram negative
Fungi
Regarding the drugs administered, 76.9% (n=70) of the
patients received antibiotics, of which the ones with the
highest prescription were cephalosporins in 58.6%
(n=41) and glycopeptides in 40% ( n=28), it is also
important to mention that 40% (n=25) patients received
carbapenems and macrolides such as azithromycin
were used in 17.1% (n=12). Antiparasitic were
administered in 25.3% (n=23) of the patients,

hydroxychloroquine in 17.4% (n=4). Antipyretics,
mainly paracetamol, were used in 89% (n=81) patients,
while 18.7 (n=17) received anticoagulants, 31.9% (n=29)
corticosteroids, and 28.6 (n=26) vasoactive drugs.
Regarding MIS-C, 5.5% (n=5) of patients received
human immunoglobulin (Table 6).

Table 6. Frequency of drug prescription in patients with COVID-19 seen at INSN SB (n=91).

Medicines
Antibiotics
Cephalosporins
Glycopeptides
Carbapenems
Penicillins +
Beta lactamase
inhibitors
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Macrolides
Aminoglycosides
Lincosamides
Penicillins
Sulfonamides
Quinolones
Oxazolidinones
Nitrofurones

17,14
12,86
12,86
11,43
10
4,29
1,43
1,43
8,8
87,5
12,5
1,1

Antifungals
Azoles
Echinocandins
Antivirals
Nucleotide analogues
(Acyclovir)

100

Antiparasitics

25,3
86,96

Nitroimidazoles
4 amino-quinolines
(Hydroxychloroquine)
Benzimidazoles

17,39
4,35
18,7

Anticoagulants
Low molecular weight
heparin (Enoxaparin)

DISCUSSION
In this study, it was found that most of the patients
presented a mild to moderate clinical picture, almost a
third of the patients required admission to the PICU in
the context of associated comorbidities. In addition, a
group of patients with diagnostic criteria for MIS-C is
described, all of whom evolved favorably.

71

literature the presentation of gastrointestinal
manifestations is variable and is currently described in
more than 20% of cases

(6,13,16)

. Similar to other studies,

the most frequent coinfection was Mycoplasma
pneumoniae and to a lesser extent with other
respiratory viruses (14,17,18). In this regard, it has been
described that respiratory viral infections could
predispose the development of super aggregated

Similar to what was reported in our study, according to
the CDC, the median age of 576 hospitalized children
was eight years (13), with a predominance of males (13,14). In
addition, only a third of our patients had family contact
(26.4%), unlike what was reported in other studies
where they indicate a history of family contact in more
than 40% of cases (14,15), this nding can be explained due
to the lack of information about the diagnosis in the
family environment.

bacterial infections such as M. pneumoniae, due to
altered respiratory mucociliary clearance and immune
system response (19) ; however, M. pneumoniae infection
could also precede viral infection (20).
Similar to what we reported, it was found that the most
frequent comorbidities were neurological in 11%
(65/614) and hematological-oncological in 8% (45/614)
(6)

. However, another study found comorbidity more

asthma (12.3%), followed by sickle cell anemia (7%) (21),
Although in our study respiratory symptoms and fever
were the most frequent clinical manifestations, 33% of
patients presented gastrointestinal symptoms, in the

many of these comorbidities are related to congenital
pathologies, unlike in adults. According to severity, in
our study it was reported that 68.2% of patients in the
Pág. 773
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PICU presented comorbidities, being a high percentage
as in another study that describes more than 80% of
patients hospitalized in the PICU with comorbidities (4).
We observed an elevation of CRP and D-dimer, in
accordance with what was found in the literature, a
variety of laboratory alterations have been described in
COVID-19, especially serum in ammatory markers
(6,15,22,23)
. One study found levels elevated CRP,
procalcitonin, interleukin-6, ferritin, and D-dimer, in
relation to severity (22). Our ndings may be due to the
higher proportion of patients with mild and moderate
symptoms and because only the initial tests are
included in the analysis.

suspicion of bacterial infection in patients with COVID19.
In our study, the use of hydroxychloroquine was rarely
used and the use of immunoglobulin was reserved
mainly for patients with MIS-C criteria, while in a
systematic review 7.8% of children received
hydroxychloroquine, 4.1% corticosteroids and 3 .1%
immunoglobulin (15). Regarding hydroxychloroquine, the
ndings can be explained by the little scienti c
evidence initially reported on it, unlike intravenous
immunoglobulin, which is accepted as
immunomodulatory therapy in the management of

In relation to the cases of MIS-C, in our study we found
six patients with a diagnosis of MIS-C and two required
PICU admission similar to that described in another
Peruvian report (1/8) (23), while in another study they
found that MIS-C cases are 5 times more likely to be
admitted to the PICU, however, no patient with MIS-C
died (6). In both studies, all progressed favorably. In
contrast, a systematic review of MIS-C in children and
adolescents reported that MIS-C appears to be a more
severe condition with 68% (531/783) of cases requiring
PICU admission (24).
Antibiotic prescription was high despite having few
microbiological ndings. In the literature, a metaanalysis describes both in adults and children that
71.3% had a prescription for antibiotics, despite the fact
that the prevalence of bacterial coinfections and COVID19 was low and the frequency of secondary bacterial
infection in patients was 14 ,3% (26), these results suggest
that antibiotics should be prescribed under a clear

Contribuciones de autoría: C.Ch., M.L, J.M., B.S., D.P.,
R.P., F.M., A.M, and J.W.L planned the study. C.Ch., M.L,
J.M., B.S., D.P., R.P., J.B., M.S. and J.W.L collected the
data. C.Ch., J.W.L and M.L. performed the statistical
analysis and the generation of gures. All authors
reviewed the manuscript.

Kawasaki disease and in the MIS-C (6,23,26,27).
Our study has some limitations, such as presenting
retrospective observational information, lack of
complete baseline tests for COVID-19, partly explained
by the diversity of clinical criteria for the request.
Regarding the diagnosis of MIS-C, not all patients
underwent a serological test for SARS-CoV 2, and only
those with a positive con rmatory test were included in
the present study.

CONCLUSIONS
In conclusion, SARS CoV-2 infection in children presents
mild and moderate clinical manifestations. Finally, a
group of patients presented comorbidities, this being
greater in those admitted to the PICU and in those who
died.

Con cts of interest: The authors declare that this
research had not any conict of interest.
Received: july 01, 2022
Approved: august 19, 2022

Funding sources: Self nanced.

Correspondence: Christian Manuel Chiara Chilet.
Adress: Av. Agustin de la Rosa T oro 1399 - San Borja.
Telephone number: (511) 230 0600
E-mail: cchiarach@insnsb.gob.pe

Pág. 774
https://inicib.urp.edu.pe/rfmh/vol22/iss4/12
DOI: https://doi.org/10.25176/RFMH.v22i4.5094

10

Chiara Chilet et al.: Clinical-epidemiological and treatment characteristics of childre

REFERENCIAS
1. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better
prognosis than adults. Acta Paediatr [Internet]. 2020 [citado el 25 de marzo de 2022];
109(6):1088–95. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32202343/
2. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 among children
in China. Pediatrics [Internet]. 2020 [citado el 25 de marzo de 2022]; 145(6):e20200702.
Disponible en: https://pubmed.ncbi.nlm.nih.gov/32179660/
3. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease
Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel
coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi [Internet].
2020 [citado el 25 de marzo de 2022]; 41(2):145–51. Disponible en:
https://pubmed.ncbi.nlm.nih.gov/32064853/
4. Shekerdemian LS, Mahmood NR, Wolfe KK, Riggs BJ, Ross CE, McKiernan CA, et al.
Characteristics and outcomes of children with Coronavirus disease 2019 (COVID-19)
infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr
[Internet]. 2020 [citado el 25 de marzo de 2022]; 174(9):868–73. Disponible en:
https://jamanetwork.com/journals/jamapediatrics/fullarticle/2766037
5. Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem
in ammatoy syndrome in children and adolescents. Lancet Infect Dis [Internet]. 2020
[citado el 25 de marzo de 2022]; 20(11):e276–88. Disponible en:
https://pubmed.ncbi.nlm.nih.gov/32818434/
6. Swann OV, Holden KA, Turtle L, Pollock L, Fairfeld CJ, Drake TM, et al. Clinical
characteristics of children and young people admitted to hospital with covid-19 in United
Kingdom: prospective multicentre observational cohort study. BMJ [Internet]. 2020
[citado el 25 de marzo de 2022]; 370:m3249. Disponible en:
https://www.bmj.com/content/370/bmj.m3249
7. Ministerio de Salud del Perú. Situación actual: Brote de COVID-19 en Perú 2020. [citado el
2 5
d e
m a r z o
d e
2 0 2 2 ] .
D i s p o n i b l e
e n :
https://www.dge.gob.pe/portal/docs/tools/coronavirus/analisiscoronavirus080520.pdf
8. Centro Nacional de Epidemiología, Prevención y Control de Enfermedades. Ministerio de
Salud del Perú. Alerta Epidemiológica Código: AE-019-2020 2020. Disponible en:
https://www.dge.gob.pe/portal/docs/alertas/2020/AE019.pdf.
y syndrome in children and
9. World Health Organization. Multisystem in ammato
adolescents temporally related to COVID-19: Scientifc Brief 2020. Disponible en:
https://www.who.int/news-room/commentaries/detail/multisystem-infammatorysyndrome-in-children-and-adolescents-with-covid-19.
10. Universidad Nacional Mayor de San Marcos. Gestión en Salud: SIS-GalenPlus 2020
Disponible en: http://gestionensalud.medicina.unmsm.edu.pe/?tool=sis-galenplus.
11. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
capture (REDCap)--a metadata-driven methodology and work owprocess for providing
translational research informatics support. J Biomed Inform [Internet]. 2009 [citado el 25
de marzo de 2022]; 42(2):377–81. Disponible en:
https://pubmed.ncbi.nlm.nih.gov/18929686
12. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap
consortium: Building an international community of software platform partners. J
Biomed Inform [Internet]. 2019 [citado el 25 de marzo de 2022];95(103208):103208.
Disponible en: https://pubmed.ncbi.nlm.nih.gov/31078660/
13. Kim L, Whitaker M, O'Halloran A, Kambhampati A, Chai SJ, Reingold A, et al.
Hospitalization rates and characteristics of children aged <18 years hospitalized with
laboratory-con rmedCOVID-19 - COVID-NET, 14 states, March 1-July 25, 2020. MMWR
Morb Mortal Wkly Rep [Internet]. 2020 [citado el 25 de marzo de 2022]; 69(32):1081–8.
Disponible en: https://pubmed.ncbi.nlm.nih.gov/32790664/
14. Hoang A, Chorath K, Moreira A, Evans M, Burmeister-Morton F, Burmeister F, et al. COVID19 in 7780 pediatric patients: A systematic review. EClinicalMedicine [Internet]. 2020
[citado el 25 de marzo de 2022]; 24(100433):100433. Disponible en:
https://pubmed.ncbi.nlm.nih.gov/32766542/

16 . Götzinger F, Santiago-García B, Noguera-Julián A, Lanaspa M, Lancella L, Calò Carducci FI,
et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort
study. Lancet Child Adolesc Health [Internet]. 2020 [citado el 25 de marzo de 2022];
4(9):653–61. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32593339/
17 . Zhang C, Gu J, Chen Q, Deng N, Li J, Huang L, et al. Clinical and epidemiological
characteristics of pediatric SARS-CoV-2 infections in China: A multicenter case series.
PLoS Med [Internet].
2020;
17(6):e1003130.
Disponible
en:
http://dx.doi.org/10.1371/journal.pmed.1003130
18. Wu Q, Xing Y, Shi L, Li W, Gao Y, Pan S, et al. Coinfection and other clinical characteristics of
COVID-19 in children. Pediatrics [Internet]. 2020 [citado el 25 de marzo de 2022];
146(1):e20200961. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32376725/
19. Morris DE, Cleary DW, Clarke SC. Secondary bacterial infections associated with in uenza
pandemics.
Front Microbiol [Internet].
2017; 8:1041. Disponible
en:
http://dx.doi.org/10.3389/fmicb.2017.01041
20. Chiu C-Y, Chen C-J, Wong K-S, Tsai M-H, Chiu C-H, Huang Y-C. Impact of bacterial and viral
coinfection on mycoplasmal pneumonia in childhood community-acquired pneumonia.
J Microbiol Immunol Infect [Internet]. 2015 [citado el 25 de marzo de 2022]; 48(1):51–6.
Disponible en: https://pubmed.ncbi.nlm.nih.gov/23927825/
21. Foster CE, Moulton EA, Munoz FM, Hulten KG, Versalovic J, Dunn J, et al. Coronavirus
disease 2019 in children cared for at Texas children's hospital: Initial clinical characteristics
and outcomes. J Pediatric Infect Dis Soc [Internet]. 2020 [citado el 25 de marzo de 2022];
9(3):373–7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32504532/
22. Zachariah P, Johnson CL, Halabi KC, Ahn D, Sen AI, Fischer A, et al. Epidemiology, clinical
features, and disease severity in patients with Coronavirus disease 2019 (COVID-19) in a
children's hospital in New York City, New York. JAMA Pediatr [Internet]. 2020 [citado el 5 de
abril
de 2022];
174(10):e202430.
Disponible
en:
https://pubmed.ncbi.nlm.nih.gov/32492092/
23. Coll-Vela LED, Zamudio-Aquise MK, Nuñez-Paucar H, Bernal-Mancilla RR, Schult-Montoya
SC, Ccorahua-De La Paz M, et al. Síndrome in amatorio multisistémico asociado a COVID19 en niños: serie de casos en un hospital pediátrico de Perú. Rev Peru Med Exp Salud
Pública [Internet]. 2020 [citado el 5 de abril de 2022]; 37(3):559–65. Disponible en:
http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S172646342020000300559
24. Radia T, Williams N, Agrawal P, Harman K, Weale J, Cook J, et al. Multi-system in ammatory
syndrome in children & adolescents (MIS-C): A systematic review of clinical features and
presentation. Paediatr Respir Rev [Internet]. 2021 [citado el 5 de abril de 2022];38:51–7.
Disponible en: https://pubmed.ncbi.nlm.nih.gov/32891582/
25. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial coinfection and secondary infection in patients with COVID-19: a living rapid review and
meta-analysis. Clin Microbiol Infect [Internet]. 2020 [citado el 5 de abril de 2022];
26(12):1622–9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32711058/
26. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis,
treatment, and long-term management of Kawasaki disease: a statement for health
professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki
Disease, Council on Cardiovascular Disease in the Young, American Heart Association: A
statement for health professionals from the committee on rheumatic fever, endocarditis
and Kawasaki disease, council on cardiovascular disease in the young, American Heart
Association. Circulation [Internet]. 2004 [citado el 5 de Abril de 2022];110(17):2747–71.
Disponible en: https://pubmed.ncbi.nlm.nih.gov/15505111/
27. Pouletty M, Borocco C, Ouldali N, Caseris M, Basmaci R, Lachaume N, et al. Paediatric
multisystem in ammatory syndrome temporally associated with SARS-CoV-2 mimicking
Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann Rheum Dis [Internet]. 2020
[citado
el 5 de abril de 2022]; 79(8):999–1006.
Disponible
en:
https://pubmed.ncbi.nlm.nih.gov/32527868/

15. Fang F, Luo XP. Facing the pandemic of 2019 novel coronavirus infections: the pediatric
perspectives. Zhonghua Er Ke Za Zhi [Internet]. 2020 [citado el 25 de marzo de 2022];
58(0):E001. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32023678/

Pág. 775

Published by INICIB-URP, 2021

11

